环泊酚注射液与甲芬那酸胶囊在健康受试者中的药物相互作用研究
结果显示,联用甲芬那酸后环泊酚暴露量无显著差异,麻醉深度指标MOAA/S和BIS曲线基本重合,不良事件均为轻度,提示甲芬那酸对环泊酚的药代动力学和药效学无显著影响。
要点
- 甲芬那酸(UGT1A9抑制剂)对环泊酚的药代动力学无显著影响。
- 联用甲芬那酸后环泊酚的麻醉效果(MOAA/S和BIS)未受影响。
- 联用时不良事件均为轻度,环泊酚安全性和耐受性良好。
核心结论
- 甲芬那酸对环泊酚在健康受试者中的药代动力学和药效学无显著影响。
- 环泊酚与甲芬那酸联用时安全且耐受性良好。
研究设计与样本
- 环泊酚(0.4 mg kg-1)在第1天和第5天单次给药;甲芬那酸第4天口服负荷剂量500 mg,随后每6小时给予维持剂量250 mg,共8剂。
- 采集血样进行药代动力学分析,采用MOAA/S量表和BIS监测麻醉深度。
主要发现
- 与单用环泊酚相比,联用甲芬那酸后Cmax、AUC0-last和AUC0-inf的几何均值比(GMR)及90%CI分别为91.6%(86.5-96.9%)、103.3%(100.3-106.4%)和107.0%(101.2-113.2%)。
- 两个治疗周期的MOAA/S和BIS曲线基本重合,表明甲芬那酸不影响环泊酚的麻醉效果。
- 单用环泊酚时7名受试者(35%)报告8例不良事件;联用甲芬那酸时12名受试者(60%)报告18例不良事件,所有不良事件均为轻度。
临床怎么用
- 临床联用甲芬那酸时无需针对环泊酚进行剂量调整。
- 联用期间仍需常规监测麻醉深度和不良事件。
局限性
- 研究为单中心、开放标签设计。
- 未涉及肝肾功能不全等特殊人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate the drug-drug interaction (DDI) of ciprofol injectable emulsion and mefenamic acid capsules in healthy subjects. METHODS: Twenty healthy subjects were enrolled in this single-centre, open-label, two-period DDI study. Ciprofol (0.4 mg kg-1 ) was administered as a single dose on days 1 and 5. A 500-mg oral loading dose of mefenamic acid was given on day 4 followed by a 250-mg maintenance dose every 6 h (a total of eight doses). Blood samples for pharmacokinetic analyses were collected. Depth of anaesthesia was monitored using the Modified Observer's Assessment of Alertness and Sedation (MOAA/S) scale and Bispectral Index scores (BISs). RESULTS: Compared with administration of ciprofol alone, administration with mefenamic acid showed no significant difference in exposure. The geometric mean ratios (GMRs) and their 90% confidence intervals (CIs) for maximum plasma concentration (Cmax ), area under the plasma concentration-time curve calculated from 0 to the last measurement point (AUC0-last ) and AUC to infinity (AUC0-inf ) were 91.6% (86.5-96.9%), 103.3% (100.3-106.4%) and 107.0% (101.2-113.2%), respectively. The MOAA/S and BIS curves for the two treatment periods essentially coincided, indicating that the anaesthesia effect of ciprofol was not affected by mefenamic acid. Seven subjects (35%) reported eight adverse events (AEs) when ciprorol was administered alone and 12 subjects (60%) reported 18 AEs when ciprofol was administered in combination with mefenamic acid. All AEs were mild. CONCLUSIONS: Mefenamic acid, a UGT1A9 inhibitor, had no significant effect on the pharmacokinetics and pharmacodynamics of ciprofol in healthy subjects. Ciprofol was safe and well tolerated when administered with mefenamic acid.
引用
- Yang D, Hu Y, Ruan Z, et al. Drug-drug interaction of ciprofol injectable emulsion with mefenamic acid capsules in healthy subjects. Br J Clin Pharmacol. 2023. PMID: 37309663. doi:10.1111/bcp.15822
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。